XL413 e F SKI-II treatment inhibited SphK1 activation

SKI-II treatment inhibited SphK1 activation

In mouse xenograft models of Bel-7402

0000000000000685

Treatment with Abiraterone significantly inhibited CRPC progression in the robustly growing subset

Unnatural amino acid that induces red shift when incorporated into fluorescent proteins and fluorescent protein-based biosensors

XL413 e F SKI-II treatment inhibited SphK1 activationBMS 863233, also known as XL 413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS 863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7 overexpressing tumor cells. CDC7, a serine threonine kinase